Michael Bern, MD PhD

Michael Bern, MD PhD

Hometown: Roanoke, VA
Medical School: Washington University in St. Louis
Residency: Washington University in St. Louis/Barnes-Jewish Hospital
Research/Academic Interests: Basic and translational research in hematologic malignancies; cancer immunotherapy
Bio: I enjoy walking my dog in the park, playing tennis and basketball, and watching Duke basketball.

Selected Publications/Abstracts

  • Wan F, Weaver A, Gao X, Bern M, Hardwidge PR, Lenardo MJ. IKKbeta phosphorylation regulates RPS3 nuclear translocation and NF-kappaB function during infection with Escherichia coli strain O157:H7. Nature immunology. 2011;12(4):335-43. Epub 2011/03/15. doi: 10.1038/ni.2007. PubMed PMID: 21399639; PubMed Central PMCID: PMCPMC3062687.
  • Henriques T, Gilchrist DA, Nechaev S, Bern M, Muse GW, Burkholder A, Fargo DC, Adelman K. Stable pausing by RNA polymerase II provides an opportunity to target and integrate regulatory signals. Molecular cell. 2013;52(4):517-28. Epub 2013/11/05. doi: 10.1016/j.molcel.2013.10.001. PubMed PMID: 24184211; PubMed Central PMCID: PMCPMC3845087.
  • Ebihara T, Song C, Ryu SH, Plougastel-Douglas B, Yang L, Levanon D, Groner Y, Bern MD, Stappenbeck TS, Colonna M, Egawa T, Yokoyama WM. Runx3 specifies lineage commitment of innate lymphoid cells. Nature immunology. 2015;16(11):1124-33. Epub 2015/09/29. doi: 10.1038/ni.3272. PubMed PMID: 26414766; PubMed Central PMCID: PMCPMC4618046.
  • Bern MD, Beckman DL, Ebihara T, Taffner SM, Poursine-Laurent J, White JM, Yokoyama WM. Immunoreceptor tyrosine-based inhibitory motif-dependent functions of an MHC class I-specific NK cell receptor. Proceedings of the National Academy of Sciences of the United States of America. 2017;114(40):E8440-e7. Epub 2017/09/20. doi: 10.1073/pnas.1713064114. PubMed PMID: 28923946; PubMed Central PMCID: PMCPMC5635927.
  • Bern MD, Parikh BA, Yang L, Beckman DL, Poursine-Laurent J, Yokoyama WM. Inducible down-regulation of MHC class I results in natural killer cell tolerance. The Journal of experimental medicine. 2019;216(1):99-116. Epub 2018/12/19. doi: 10.1084/jem.20181076. PubMed PMID: 30559128; PubMed Central PMCID: PMCPMC6314522.
  • Lauron EJ, Yang L, Harvey IB, Sojka DK, Williams GD, Paley MA, Bern MD, Park E, Victorino F, Boon ACM, Yokoyama WM. Viral MHCI inhibition evades tissue-resident memory T cell formation and responses. The Journal of experimental medicine. 2019;216(1):117-32. Epub 2018/12/19. doi: 10.1084/jem.20181077. PubMed PMID: 30559127; PubMed Central PMCID: PMCPMC6314518.
  • Park E, Patel S, Wang Q, Andhey P, Zaitsev K, Porter S, Hershey M, Bern M, Plougastel-Douglas B, Collins P, Colonna M, Murphy KM, Oltz E, Artyomov M, Sibley LD, Yokoyama WM. Toxoplasma gondii infection drives conversion of NK cells into ILC1-like cells. eLife. 2019;8. Epub 2019/08/09. doi: 10.7554/eLife.47605. PubMed PMID: 31393266; PubMed Central PMCID: PMCPMC6703900.
  • Ferris ST, Durai V, Wu R, Theisen DJ, Ward JP, Bern MD, Davidson JTt, Bagadia P, Liu T, Briseño CG, Li L, Gillanders WE, Wu GF, Yokoyama WM, Murphy TL, Schreiber RD, Murphy KM. cDC1 prime and are licensed by CD4(+) T cells to induce anti-tumour immunity. Nature. 2020;584(7822):624-9. Epub 2020/08/14. doi: 10.1038/s41586-020-2611-3. PubMed PMID: 32788723; PubMed Central PMCID: PMCPMC7469755.
  • Parikh BA, Bern MD, Piersma SJ, Yang L, Beckman DL, Poursine-Laurent J, Plougastel-Douglas B, Yokoyama WM. Control of Viral Infection by Natural Killer Cell Inhibitory Receptors. Cell Rep. 2020;32(4):107969. Epub 2020/07/30. doi: 10.1016/j.celrep.2020.107969. PubMed PMID: 32726632; PubMed Central PMCID: PMCPMC7458139.